Q4 EPS Estimate for Vir Biotechnology Raised by Analyst

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for Vir Biotechnology in a report released on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn ($0.62) per share for the quarter, up from their prior estimate of ($0.68). The consensus estimate for Vir Biotechnology's current full-year earnings is ($3.92) per share. Leerink Partnrs also issued estimates for Vir Biotechnology's FY2026 earnings at ($2.43) EPS, FY2027 earnings at ($1.58) EPS and FY2028 earnings at ($0.64) EPS.

Several other equities analysts have also recently weighed in on VIR. Needham & Company LLC reaffirmed a "buy" rating and issued a $14.00 price target on shares of Vir Biotechnology in a research report on Thursday, May 22nd. Raymond James Financial began coverage on shares of Vir Biotechnology in a research report on Friday, July 11th. They issued an "outperform" rating on the stock. Finally, The Goldman Sachs Group dropped their price target on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $30.25.

Vir Biotechnology Trading Up 0.3%

NASDAQ VIR traded up $0.01 during trading hours on Monday, hitting $4.45. The company's stock had a trading volume of 171,426 shares, compared to its average volume of 1,569,555. Vir Biotechnology has a 52 week low of $4.16 and a 52 week high of $14.45. The company has a market capitalization of $618.75 million, a PE ratio of -1.11 and a beta of 1.18. The company's 50-day simple moving average is $5.24 and its two-hundred day simple moving average is $6.31.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.08). The company had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%. Vir Biotechnology's revenue for the quarter was down 60.5% compared to the same quarter last year. During the same period last year, the company earned ($1.02) EPS.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $5.47, for a total transaction of $37,174.12. Following the transaction, the executive vice president owned 108,204 shares of the company's stock, valued at $591,875.88. This trade represents a 5.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $5.10, for a total transaction of $112,200.00. Following the transaction, the director directly owned 1,298,391 shares in the company, valued at approximately $6,621,794.10. This represents a 1.67% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,582 shares of company stock worth $294,930. Insiders own 16.00% of the company's stock.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Vir Biotechnology during the 2nd quarter worth approximately $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vir Biotechnology during the 4th quarter worth approximately $42,000. GAMMA Investing LLC increased its stake in shares of Vir Biotechnology by 524.3% during the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock worth $46,000 after purchasing an additional 5,972 shares during the last quarter. Apollon Wealth Management LLC purchased a new stake in shares of Vir Biotechnology during the 2nd quarter worth approximately $50,000. Finally, Daiwa Securities Group Inc. increased its stake in shares of Vir Biotechnology by 2,200.6% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company's stock worth $62,000 after purchasing an additional 11,773 shares during the last quarter. Institutional investors own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).